Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Florbetaben PET in preclinical familial Alzheimer's disease mutation carriers
2014-000763-41Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flutemetamol in Alzheimer's disease (AD), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Incidence of adverse events after single-dose florbetaben. Started Jul 2014; status: terminated.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-000763-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000763-41.